Factor Xa - A promising target for drug development

Cellular and Molecular Life Sciences

Volumn 59, Issue 2, 2002, Pages 189-192

  Kaiser, B ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANTICOAGULATION; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; INFLAMMATORY DISEASE; REVIEW; THROMBIN TIME;

ANTICOAGULANTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS; FACTOR XA; HUMANS;

EID: 0036180835     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-002-8415-9     Document Type: Review

References (40)

1. The coagulation explosion
2. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions: Resolution of the antithrombin conformational change contribution to heparin rate enhancement
3. Mechanism of heparin activation of antithrombin: Evidence for an induced-fit model of allosteric activation involving two interaction subsites
4. Identification of effector cell protease receptor-1: A leukocyte-distributed receptor for the serine protease factor Xa
5. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa
6. Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF
7. The elusive factor Xa receptor: Failure to detect transcripts that correspond to the published sequence of EPR-1
8. Gene induction by coagulation factor Xa is mediated by activation of protease-activated receptor 1
9. Factor Xa-evoked relaxation in rat aorta: Involvement of PAR-1
10. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo
11. A synthetic inhibitor of factor Xa, DX-9065a, reducesproliferation of vascular smooth muscle cells in vivo in rats
12. Role of thrombin compared with factor Xa in the procoagulant activity of whole blood clots
13. Prolonged activation of prothrombin on the vascular wall after arterial injury
14. Thrombin and factor Xa inhibitors
15. Factor Xa inhibitors as novel antithrombotic agents: Facts and perspectives
16. Synthetic and recombinant antithrombin drugs
17. Coagulation factor Xa: The prothrombinase complex as an emerging therapeutic target for small molecule inhibitors
18. Progress in the design of inhibitors of coagulation factor Xa
19. Factor Xa inhibitors
20. Factor Xa inhibitors: Recent advances in anticoagulant agents
21. New advances in the discovery of thrombin and factor Xa inhibitors
22. Perspectives on factor Xa inhibition
23. Recent advances in factor Xa inhibitors
24. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity
25. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
26. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540)
27. Factor Xa inhibitors: Today and beyond
28. Recent advances in clinical trials of the direct and indirect selective factor Xa inhibitors
29. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers
30. Assessment of the pharmacodynamic profile of DX9065a, a direct factor Xa inhibitor, in 36 healthy male subjects: A first study using subcutaneous route
31. Pharmacokinetic and pharmacodynamic responses of the novel factor Xa inhibitor DX-9065a: Results from the Xa neutralization for atherosclerotic disease understanding (XaNADU) IB trial
32. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: A comparative study in humans vs low molecular weight heparin
33. Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice
34. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The Ephesus study
35. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective hip replacement surgery: The Pentathlon 2000 study
36. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following elective major knee surgery: The Pentamaks study
37. Efficacy of the first synthetic factor Xa inhibitor, pentasaccharide Org31540/SR90107A, versus low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) following hip fracture surgery: The Penthifra study
38. The role in cardiology of the first synthetic factor Xa inhibitor: Lessons from the results of the clinical programme in venous thromboembolism
39. A synthetic factor-Xa inhibitor (ORG31540/SR90107A) as an adjunct to fibrinolysis in acute myocardial infarction: The PENTALYSE study
40. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors